References for the
GERI-RxFiles 3rd Edition

Assessing Medications in Older Adults
Alternatives to explore, when less may be more

Geri
Rx Files
2019
www.RxFiles.ca
# Geriatric Rx Files Table of Contents - 3rd Edition

## Introduction

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Therapy in the Older Adult: Considerations for Optimal Prescribing, Prescribing Cascade &amp; Deprescribing</td>
<td>1-3</td>
</tr>
<tr>
<td>New Frailty, Clinical Frailty Scale <em>(from EGMR, Dalhousie – with permission from Kenneth Rockwood, MD)</em></td>
<td>4-5</td>
</tr>
</tbody>
</table>

## Cardiology

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiplatelets &amp; Anticoagulants: DAPT, Dual &amp; Triple Therapy</td>
<td>6-9</td>
</tr>
<tr>
<td>Atrial Fibrillation: Antithrombotics for Stroke Prevention</td>
<td>10-17</td>
</tr>
<tr>
<td>Atrial Fibrillation: Rate versus Rhythm Control</td>
<td>18-20</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>21-24</td>
</tr>
<tr>
<td>Heart Failure with Reduced Ejection Fraction</td>
<td>25-32</td>
</tr>
<tr>
<td>Hypertension</td>
<td>33-44</td>
</tr>
<tr>
<td>QT Prolongation &amp; Torsades de Pointes: Drugs &amp; Sudden Death</td>
<td>45-46</td>
</tr>
<tr>
<td>Stable Ischemic Heart Disease</td>
<td>47-54</td>
</tr>
</tbody>
</table>

## Endocrine & Metabolic

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>55-63</td>
</tr>
<tr>
<td>Diabetes Agents – Outcomes Comparison Summary Table (a colour comparison)</td>
<td>64</td>
</tr>
<tr>
<td>New Diabetes: Deprescribing Algorithm for Antihyperglycemics <em>(from deprescribing.org)</em></td>
<td>65-66</td>
</tr>
</tbody>
</table>

## Gastrointestinal

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid Suppression</td>
<td>67-72</td>
</tr>
<tr>
<td>PPI Formulations &amp; Alternative Routes of Administration</td>
<td>73</td>
</tr>
<tr>
<td>New PPI Deprescribing Algorithm <em>(from deprescribing.org)</em></td>
<td>74-75</td>
</tr>
<tr>
<td>Constipation</td>
<td>76-81</td>
</tr>
</tbody>
</table>

## Genitourinary

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal Insufficiency</td>
<td>82-86</td>
</tr>
<tr>
<td>Urinary Incontinence</td>
<td>87-94</td>
</tr>
<tr>
<td>Urinary Tract Infections</td>
<td>95-98</td>
</tr>
</tbody>
</table>

## Musculoskeletal & Connective Tissue

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Falls</td>
<td>99-101</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>102-106</td>
</tr>
<tr>
<td>Pain Management</td>
<td>107-115</td>
</tr>
</tbody>
</table>

## Neurology & Psychiatry

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergics: Reference List of Medications with Anticholinergic Effects</td>
<td>116-117</td>
</tr>
<tr>
<td>Dementia &amp; Cognitive Impairment</td>
<td>118-122</td>
</tr>
<tr>
<td>Dementia: Behavioural &amp; Psychological Symptoms</td>
<td>123-133</td>
</tr>
<tr>
<td>New Dementia: Deprescribing Algorithm for Cholinesterase Inhibitors &amp; Antipsychotics <em>(from deprescribing.org)</em></td>
<td>134-137</td>
</tr>
<tr>
<td>Depression</td>
<td>138-145</td>
</tr>
<tr>
<td>New Insomnia &amp; Deprescribing Algorithm <em>(from deprescribing.org)</em></td>
<td>146-152</td>
</tr>
</tbody>
</table>

Available: [http://ageing.oxfordjournals.org/content/44/2/213.long](http://ageing.oxfordjournals.org/content/44/2/213.long)
[http://ageing.oxfordjournals.org/content/44/2/213/suppl/DC1](http://ageing.oxfordjournals.org/content/44/2/213/suppl/DC1)


INTRODUCTION
Drug Therapy in the Older Adult: Considerations for Optimal Prescribing, Prescribing Cascade & Deprescribing


Additional References:


AGS Geriatric Evaluation and Management Tools:
http://familymed.uthscsa.edu/gerifellowship/redirect/articles/CLC/Geriatrics%20Eval%20Management%20Tool%20for%20Frailty.pdf
INTRODUCTION
Frailty in Older Adults


CARDIOLOGY
Antiplatelets & Anticoagulants: DAPT, Dual & Triple Therapy

CARDIOVASCULAR INDICATIONS

Guidelines


Trials

- Mehta SR, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000 Dec; 21(24):2033-41.
DAPT POST-PCI META-ANALYSES


CEREBROVASCULAR INDICATIONS

GUIDELINES


TRIALS


PL Detail-Document, **STARTing and STOPPing Medications in the Elderly.** Pharmacist’s Letter/Prescriber’s Letter. September 2011.


Jin M, Kosar L. **Atrial fibrillation.** RxFiles 9th ed. Saskatoon, SK: RxFiles; 2012.


Dumont Z, Kosar L. **Warfarin tips & dosing nomograms.** Saskatoon, SK: RxFiles; 2013.


Additional References:

Atrial Fibrillation: Rate versus Rhythm Control in Older Adults

- Jin M, Kosar L. Atrial fibrillation. RxFiles 9th ed. Saskatoon, SK: RxFiles; 2012.
- Dumont Z, Kosar L. Warfarin tips & dosing nomograms. Saskatoon, SK: RxFiles; 2013.
Dyslipidemia in Older Adults


52. Kerr, R. *Choosing Wisely Newsletter.* Hamilton Family Health Team. July 2018
Chronic Heart Failure with Reduced Ejection Fraction (≤40%) in Older Adults


24. Thiazide Diuretics. CPhA Monograph, RxTx, accessed online July 21, 2018


55. Mann J, Hilgers K. Use of thiazide diuretics in patients with primary (essential) hypertension. UpToDate, accessed July 29, 2019

Additional References:
<table>
<thead>
<tr>
<th>Trial name</th>
<th>Reference &amp; Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLHAT</td>
<td>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002;288:2981-2997.</td>
</tr>
</tbody>
</table>

- Sudden Arrhythmia Death Syndromes Foundation. The long QT syndrome. SADS Foundation http://www.sads.org/LQTflyer.pdf (Cardiac Arrhythmia Reasearch & Education Foundation www.longqt.org)
- Woefel JA. Drug-Induced Long QT Interval & Sudden Cardiac Death. Pharmacist's Letter Nov 2004;20:201111

Additional References:


Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of Prolonged QT Interval and Their Contribution to Sudden Death Risk in Coronary Artery Disease. The Oregon Sudden Unexpected Death Study. Circulation. 2009 Jan 26. [Epub ahead of print] Diabetes mellitus and QTc-affecting drugs determined QTc prolongation and were predictors of SCD in coronary artery disease. However, idiopathic abnormal QTc prolongation was associated with 5-fold increased odds of SCD. A continued search for novel determinants of QTc prolongation such as genomic factors is likely to enhance risk stratification for SCD in coronary artery disease.


FDA Feb/10 notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart from the use of Invirase (saquinavir) in combination with Norvir (ritonavir), antiviral medications given together to treat HIV infection. The data suggest that together the two drugs may affect the electrical activity of the heart, known as prolonged QT or PR intervals.
FDA Nov/10 is requesting that manufacturers of the painkiller propoxyphene pull the drug from the market because of concerns over cardiotoxicity. (Propoxyphene is marketed alone as Darvon & combined with acetaminophen as Darvocet.) The agency's request is based on data showing that, even when taken at therapeutic doses, the drug can lead to potentially dangerous changes in the heart’s electrical activity, including prolonged PR & QT intervals & widened QRS complex. FDA advises clinicians to stop prescribing propoxyphene and to ask current users to discontinue the drug. FDA’s MedWatch alert

FDA Dec/10 The injectable form of dolasetron mesylate (Anzemet) should not be used to prevent nausea or vomiting related to chemotherapy because the drug increases the risk for torsade de pointes, the FDA announced on Friday. The FDA recommends against using Anzemet injections in patients with congenital long-QT syndrome. The warning does not apply to Anzemet tablets because the risks for developing an abnormal heart rhythm are not as high as with the injections. FDA MedWatch alert (Free)

FDA July/11 FDA has added a warning to the label of the atypical antipsychotic quetiapine (Seroquel) cautioning about potential increases in the QT interval. Postmarketing cases of QT prolongation have been reported in some 17 patients, according to the New York Times. These patients had overdosed on quetiapine, had other illnesses, or were taking other medications that can cause electrolyte imbalance or QT prolongation.

FDA Aug/11 The antidepressant citalopram (marketed as Celexa) should not be prescribed at doses above 40 mg/day because higher dosages can cause arrhythmias, the FDA has warned.

FDA Sep/11 The U.S. Food and Drug Administration (FDA) is informing the public of an ongoing safety review of the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and their generics). Ondansetron may increase the risk of developing abnormal changes (QT prolongation & torsades) in the electrical activity of the heart.

FDA July/12 Alerting clinicians that a single 32-mg intravenous dose of ondansetron (Zofran and generics) may lead to QT interval prolongation, which in turn may put patients at risk for torsades de pointes.

FDA Dec/12 is working with the manufacturers of all 32 mg dose Ondansetron Injectable Products (brand and generic) to voluntarily recall them from the market due to QT serious cardiac toxicity.

FDA Mar/13 is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.


Health Canada Aug/10 Droperidol Injection USP is associated with severe arrhythmia (eg. QT) and the Canadian Monograph of this product has been updated to reflect this risk.

Health Canada Nov/10 Darvon-N (dextropropoxyphene) - Recall and Withdrawal in Canada - Paladin Labs Inc. Paladin Labs Inc. in collaboration with Health Canada would like to inform healthcare professionals of the voluntary recall and withdrawal of the opioid analgesic Darvon-N (dextropropoxyphene) in Canada. (widen the QRS complex, prolong the QT interval and therefore increase the risk of serious abnormal heart rhythms.)

Health Canada Feb/12 has recently approved vandetanib (CAPRELSA) to treat medullary thyroid cancer in adult patients where either the tumour cannot be removed by surgery or it has spread from the thyroid gland to other parts of the body. CAPRELSA can cause serious QT heart rhythm changes which may result in sudden death, if left untreated.

Health Canada Mar/12: Domperidone should be used at the lowest possible dose. The risk of serious ventricular arrhythmias and sudden cardiac death may be higher in patients taking daily doses greater than 30 mg, and in patients over 60 years old.

Health Canada Oct/12: Ondansetron can cause a dose-dependent prolongation of the electrocardiographic-corrected QT interval (QTc), which can lead to Torsade de Pointes, a potentially life-threatening heart rhythm abnormality. The new maximum recommended single intravenous (IV) dose of ZOFRAN ® is 16 mg infused over 15 minutes.
Health Canada Oct/13 has completed a safety review of the drug Sensipar (cinacalcet) that identified a possible link between the drug and abnormal heart rhythm (QT) associated with low blood calcium.

Health Canada Feb/14: TELZIR (fosamprenavir) should not be used with the antiarrhythmic drugs amiodarone, lidocaine (systemic), or quinidine, as this may cause serious and/or life-threatening reactions such as abnormal heart rhythm (arrhythmias). In addition, Telzir should not be used with delavirdine, another antiviral drug to treat HIV, because it may reduce the effectiveness of delavirdine.

Health Canada Mar/14: REMERON / REMERON RD (mirtazapine) – Abnormal Heart Rhythm - Merck Canada Inc. Cases of abnormal heart rhythm (eg. QT prolongation) have been reported with the antidepressant REMERON / REMERON RD (mirtazapine) mainly with drug overdose or when taking other drugs known to cause heart rhythm problems. The product information has been updated.


Krantz MJ, Martin J, et al. QTc Interval Screening in Methadone Treatment. Ann Intern Med. 2009 Jan 19. [Epub ahead print] Recommendation 1 (Disclosure): Clinicians should inform patients of arrhythmia risk when they prescribe methadone. Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope. Recommendation 3 (Screening): Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures. Recommendation 4 (Risk Stratification): If the QTc interval is greater than 450 ms but less than 500 ms, discuss the potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy. Recommendation 5 (Drug Interactions): Clinicians should be aware of interactions between methadone and other drugs that possess QT interval-prolonging properties or slow the elimination of methadone.


Krantz MJ, Martin J, et al. QTc Interval Screening in Methadone Treatment. Ann Intern Med. 2009 Jan 19. [Epub ahead print] Recommendation 1 (Disclosure): Clinicians should inform patients of arrhythmia risk when they prescribe methadone. Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope. Recommendation 3 (Screening): Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures. Recommendation 4 (Risk Stratification): If the QTc interval is greater than 450 ms but less than 500 ms, discuss the potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy. Recommendation 5 (Drug Interactions): Clinicians should be aware of interactions between methadone and other drugs that possess QT interval-prolonging properties or slow the elimination of methadone.


MHRA Dec/11 Citalopram and escitalopram are associated with dose-dependent QT interval prolongation and should not be used in those with: congenital long QT syndrome; known pre-existing QT interval prolongation; or in combination with other medicines that prolong the QT interval. ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment. For citalopram, new restrictions on the maximum daily doses now apply: 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment. For escitalopram, the maximum daily dose for patients older than 65 years is now reduced to 10 mg/day; other doses remain unchanged.

- Phillips Mark; Sullivan B; Snyder B; et al. Effect of Enzyte on QT and QTc Intervals. Arch Intern Med. 010;170(15):1402-1404.


Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial. Arch Intern Med. 2007 Dec 10;167(22):2469-75. Buprenorphine is associated with less QTc prolongation than levomethadyl or methadone and may be a safe alternative.


Stable Ischemic Heart Disease (SIHD) in Older Adults

- Boden WE, Franklin BA, Wenger NK. Physical Activity and Structured Exercise for Patients With Stable Ischemic Heart Disease. JAMA 2013;309(2):143-144.


23. Many references support the use of DPP-4s in Older Adults:


41. Cardiovascular Protection in People With Diabetes   ? (is this part of this one or separate?) Diabetes Canada Clinical Practice Guidelines Expert Committee

Additional References:

- James A. Stone MD, PhD, FRCPC, Robyn L. Houlden MD, FRCPC, Peter Lin MD, CCFP, Jacob A. Udell MD, MPH, FRCPC, Subodh Verma MD, PhD, FRCSC, FAHA
GASTROINTESTINAL

Acid Suppression in Older Adults


GASTROINTESTINAL

Constipation in Older Adults


Additional References:

- Gray JR. *What is chronic constipation? Definition and diagnosis*. Can J Gastroenterol. 2011 Oct;25 Suppl B:7B-10B.
- Pare P. *The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner*. Can J Gastroenterol. 2011 Oct 25; 25 Suppl B: 36B-40B.
- Canadian Agency for Drugs and Technologies in Health (CADTH). *Rapid Response Report: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness*. June 2014.


27. (Physiotherapy- especially if pt can’t isolate or exercising wrong muscles, or if stops breathing during Kegels; Saskatoon Health Region: Pelvic Floor Rehab Program 655-8208, typically sees females q1-2weeks x 8 times, waiting list ~6months; Private Clinics in Saskatoon also treat, quicker access, 3rd party coverage?: Bourassa & Daniels Kimber) Nurse Continence Advisor: Eliza Meggs RN,NCA (Nightingale Nursing Group) Phone: 306-652-3314


42. Robinson D, Cardozo L. **Antimuscarinic drugs to treat overactive bladder.** BMJ. 2012 Mar 27;344:e2130.


Additional References:


Additional References:

Preventing Falls in Older Adults

2. Kwan, E, Straus, SE. Assessment and Management of Falls in Older People. CMAJ. 2014 Nov;186(16):610-621.
29. The 2015 Canadian Hypertension Education Program Recommendations www.hypertension.ca


Additional References:

Osteoporosis in Older Adults


NEUROLOGY & PSYCHIATRY

Anticholinergics: Reference List of Drugs with Anticholinergic Effects


Additional References


- Anticholinergic Cognitive Burden Scale [link]


Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin 5mg/day in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008 May;56(5):862-70.


McCartney M. Margaret McCartney: Drugs with anticholinergic side effects and cognitive decline-cause or effect? BMJ. 2015 Mar 16;350:h1428.


Richardson KFox CMaidment I. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:k1315.


- Torjesen I. Anticholinergic effects of common drugs are associated with increased mortality in over 65s. BMJ. 2011 Jun 28;342:d4037.


Dementia in Older Adults: STOPP & Beers Criteria


Insomnia Disorder in Older Adults


10. Zee P, Bloom HG. Understanding and resolving insomnia in the elderly. Geriatrics 2006;61(5)Special section1-12


Additional References:


15. Spiriva product monograph
16. Indacaterol product monograph
18. Spiriva product monograph


How to Pick an Inhaler

1. A Guide to Spirometry for Primary Care Physicians by Dr. J. Lowry
Inhaler_technique_in_adults_with_asthma_or_COPD.pdf
RESPIRATORY

ASTHMA & COPD: Inhaler Technique

- Ventolin HFA. Product monograph. Copyright 2014 GlaxoSmithKline, Inc.
- Combitvent Respimat. Product monograph. Copyright 2014 Boehringer Ingelheim (Canada) Ltd.
- Spiriva. Product monograph. Copyright 2012 Boehringer Ingelheim (Canada) Ltd.
- Onbrez Breezhaler. Product monograph. Copyright 2015 Novartis Pharmaceuticals Canada Inc.
- Symbicort Turbuhaler. Product monograph. Copyright 2012 AstraZeneca Canada Inc.
- Advair Diskus. Product monograph. Copyright 2014 GlaxoSmithKline, Inc.
- Foradil. Product monograph. Copyright 2013 Novartis Pharmaceuticals Canada Inc.


**Psoriasis**


**Pruritus & Xerosis**

- Roberts WE. *Dermatologic problems of older women*. Dermatol Clin 2006; 24: 271–280
- Adis Medical Writers. *Manage chronic pruritus in the elderly with various agents depending on the pathophysiology and aetiology of the condition*. Drugs & Therapy Perspectives, 31(9), 302-306.
Pressure Ulcers

- *Canadian Best Practice Guidelines for the Prevention and Management of Pressure Ulcers in People with Spinal Cord Injury*

Chronic Urticaria

- *Omalizumab (xolair) product monograph*

Fragile Skin and Sun


Others:

Drug Interactions in Older Adults


Additional References:

Dry Eye Disease in Older Adults

Electrolyte Imbalances in Older Adults

9. Saskatoon Health Region Reference Ranges
17. Pharmacists Letter #240904 – **Potassium Content of Foods and Salt Substitutes.** September 2008
50. Guideline for replacement of magnesium. CJHP vol 52 no 6 December 1999
51. Dynamed 2015

**Additional References:**

a Lasskogen G, Jepsen SK. *Overcoming Patient Difficulty in Swallowing Tablets- Extended Release Characteristics of Pentasa (mesalamine, 5-ASA) are Maintained Following Dispersal in Water*
**MISCELLANEOUS**

**Nutritional Supplements & Dietary Considerations for Disease Management**

**General References:**
- eCPS. Available at: [https://www.e-therapeutics.ca/home.whatsnew.action](https://www.e-therapeutics.ca/home.whatsnew.action)
- Lexicomp. Available at: [http://online.lexi.com/lco/action/home/switch](http://online.lexi.com/lco/action/home/switch)
- Uptodate. Available at: [http://online.lexi.com/lco/action/home/switch](http://online.lexi.com/lco/action/home/switch)

**Calcium:**

**Co-enzyme Q10:**

**Iron:**
Magnesium:
- *Magnesium: CPhA Monograph: Magnesium Salts: Oral eCPS*

Multivitamins-Minerals:

Potassium:

Vitamin B1 (Thiamine):

Vitamin B9 (Folic acid):

Vitamin B12 (Cobalamin):

Vitamin C:
- 2012 American College of Rheumatology Guidelines for Management of Gout. *Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia*


**Vitamin D:**


**Vitamin E:**


**Vitamin K:**


**Constipation:** see Constipation in Older Adults section for references

**GERD:** see GERD in Older Adults section for references

**Heart Failure:** see Heart Failure in Older Adults for references
Gout:


Age-Related Macular Degeneration:

- Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2015 Apr 9;4:CD010015.

Urinary Tract Infections:

Other References:


Vaccines for Older Adults

GERI-RXFILES VACCINES FOR OLDER ADULTS REFERENCES:


GERI-RXFILES HERPES ZOSTER REFERENCES:

2. Shingrix®, Zostavax II® - Monographs, RxTx, accessed December 28, 2017

GERI-RXFILES PNEUMOCOCCAL DISEASES REFERENCES:


**GERI-RXFILES INFLUENZA REFERENCES:**


TAPERING MEDICATIONS IN OLDER ADULTS

3. A practical guide to stopping medications, BPJ; Issue 27; www.bpac.org.nz
4. A practical guide to stopping medications, BPJ; Issue 27; www.bpac.org.nz
17. Lamotrigine; Prepared by Lexicomp: Lexi-Drugs.
27. Mirtazapine; Prepared by Lexicomp: Lexi-Drugs.
30. Venlafaxine; Prepared by Lexicomp: Lexi-Drugs.
32. Desvenlafaxine; Prepared by Lexicomp: Lexi-Drugs.
34. Duloxetine; Prepared by Lexicomp: Lexi-Drugs.
37. Paroxetine; Prepared by Lexicomp: Lexi-Drugs.
45. Amantadine; Prepared by Lexicomp: Lexi-Drugs.
48. Pramipexole; Prepared by Lexicomp: Lexi-Drugs.
49. Ropinirole; Prepared by Lexicomp: Lexi-Drugs.
51. Ropinirole; Prepared by Lexicomp: Lexi-Drugs.
58. Risperidone; Prepared by Lexicomp: Lexi-Drugs.
59. Olanzapine; Prepared by Lexicomp: Lexi-Drugs.
61. Clozapine; Prepared by Lexicomp: Lexi-Drugs.
65. Bisoprolol, atenolol, metoprolol; Prepared by Lexicomp: Lexi-Drugs.
70. Common oral medications that may need tapering. Pharmacist’s Letter/Prescriber’s Letter 2008;24(12):241208.